Mirati Therapeutics (MRTX) Commences Dosing in Mocetinostat Phase 2

January 7, 2015 8:15 AM EST Send to a Friend
Mirati Therapeutics (NASDAQ: MRTX) announced that the first patient has been dosed in a Phase 2 clinical trial designed to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login